Viatris Unveils Late-Breaking Abstract on Cenerimod at the 26th APLAR Annual Congress
Viatris Inc. (NASDAQ: VTRS), a leading global healthcare company, today presented results from its Phase 2 study of cenerimod (ACT-333441) as a late-breaking abstract at the 26th Asia-Pacific League of…
Jazz Pharmaceuticals Updates on Phase 3 Trial of Cannabidiol for Epilepsy in Japan
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has announced the top-line results from a Phase 3 open-label, single-arm trial conducted in Japan. The study assessed the safety and efficacy of their cannabidiol…
Elanco Animal Health to Expand Production Capabilities at Kansas Manufacturing Facility
Elanco Animal Health Incorporated (NYSE: ELAN) has announced a significant expansion of its biologics manufacturing facility in Elwood, Kansas. The 25,000-square-foot expansion represents a $130 million investment that will be…
Lupin Gains Health Canada Approval for Pegfilgrastim Biosimilar
Lupin Limited, a leading global pharmaceutical company, has announced that it has received approval from Health Canada for its biosimilar Pegfilgrastim. The product, to be marketed under the brand name…
Bristol Myers Squibb’s sBLA Accepted by FDA for First-Line Treatment of Unresectable Hepatocellular Carcinoma
Bristol Myers Squibb (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for Opdivo® (nivolumab) in combination with Yervoy®…
OTEZLA® (Apremilast) Now Available in the U.S. for Moderate to Severe Pediatric Plaque Psoriasis Treatment
Amgen (NASDAQ: AMGN) has announced that Otezla® (apremilast) is now available in the U.S. for pediatric use. Earlier this year, the U.S. Food and Drug Administration (FDA) approved Otezla for…
Roche Addresses WHO’s Global Health Emergency Declaration Amid Ongoing Mpox Outbreak
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced its commitment to supporting the global response to the mpox health emergency by providing diagnostic tests specifically developed for mpox, formerly known as…
EU Approves Second Indication for TEPKINLY in Treating Relapsed/Refractory Follicular Lymphoma
AbbVie (NYSE: ABBV) has announced that the European Commission (EC) has granted conditional marketing authorization for TEPKINLY® (epcoritamab) as a monotherapy for adult patients with relapsed or refractory (R/R) follicular…
Tirzepatide Cuts Type 2 Diabetes Risk by 94% in Adults with Pre-Diabetes and Obesity or Overweight
Eli Lilly and Company (NYSE: LLY) announced today positive top-line results from the SURMOUNT-1 three-year study, which evaluated the long-term efficacy and safety of tirzepatide (Zepbound® and Mounjaro®) for weight…
Medea Inc. Teams Up with CalOptima Health to Distribute 100,000 Naloxone Units to Southern California Harm Reduction Groups
Medea Inc., a leading medical products and pharmaceutical distribution company, is at the forefront of a major initiative to tackle the opioid crisis. The company is partnering with CalOptima Health…
UptimeHealth and Darby Dental Supply Collaborate to Introduce Darby Dispatch: A New Solution for Improving Efficiency and Compliance in Dental Practices Across the Country
UptimeHealth, a leader in healthcare technology solutions, is excited to announce a strategic partnership with Darby Dental Supply, a top dental distributor in the U.S. This collaboration introduces Darby Dispatch,…
Daiwa Health Development, Inc. to Host Webinar with Dr. Fred Pescatore on Clinical Applications of RBAC
Daiwa Health Development, Inc. Announces Webinar with Dr. Fred Pescatore on Clinical Applications of RBAC Daiwa Health Development, Inc. is thrilled to host an upcoming webinar featuring Dr. Fred Pescatore,…